###begin article-title 0
Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas
###end article-title 0
###begin p 1
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 417 418 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 873 874 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1045 1046 1045 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1092 1093 1092 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1195 1196 1195 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1301 1302 1301 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1459 1460 1459 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1732 1733 1732 1733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1158 1166 <span type="species:ncbi:9606">patients</span>
###xml 1370 1378 <span type="species:ncbi:9606">patients</span>
Parafibromin is a protein encoded by the hyperparathyroidism 2 oncosuppressor gene and its downregulated expression is involved in pathogenesis of parathyroid carcinomas. To clarify the roles of parafibromin expression in tumourigenesis and progression of gastric carcinomas, it was examined by immunohistochemistry (IHC) on tissue microarray containing gastric carcinomas (n = 508), adenomas (n = 45) and gastritis (n = 49) with a comparison of its expression with clinicopathological parametres of carcinomas. Gastric carcinoma cell lines (MKN28, AGS, MKN45, KATO-III and HGC-27) were studied for parafibromin expression by IHC and western blot. Parafibromin expression was localised in the nucleus of gastric epithelial cells, adenoma, carcinoma cells and cell lines. Its expression was gradually decreased from gastritis to gastric carcinoma, through gastric adenomas (p < 0.05) and inversely correlated with tumour size, depth of invasion, lymphatic invasion, lymph node metastasis and Union Internationale Contre le Cancer (UICC) staging (p < 0.05) but not with sex or venous invasion (p > 0.05). Parafibromin was strongly expressed in older carcinoma patients compared with younger ones (p < 0.05). There was stronger positivity of parafibromin in intestinal-type than diffuse-type carcinomas (p < 0.05). Univariate analysis indicated cumulative survival rate of patients with positive parafibromin expression to be higher than without its expression (p < 0.05). Multivariate analysis showed that age, tumour size, depth of invasion, lymphatic invasion, lymph node metastasis, UICC staging and Lauren's classification but not sex, venous invasion or parafibromin expression were independent prognostic factors for carcinomas(p < 0.05). Downregulated parafibromin expression possibly contributed to pathogenesis, growth, invasion and metastasis of gastric carcinomas. It was considered as a promising marker to indicate the aggressive behaviours and prognosis of gastric carcinomas.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 684 685 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 687 688 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 817 841 817 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 1182 1184 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1186 1188 1186 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1190 1192 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1194 1196 1194 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1198 1200 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1412 1414 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1542 1543 1542 1543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1737 1739 1737 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1964 1966 1964 1966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 2092 2093 2092 2093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 2095 2097 2095 2097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 2253 2254 2253 2254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 2256 2258 2256 2258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 2280 2282 2280 2282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 477 482 <span type="species:ncbi:9606">human</span>
###xml 817 841 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 1730 1735 <span type="species:ncbi:9606">human</span>
Parafibromin is a protein encoded by the hyperparathyroidism 2 (HRPT2) oncosuppressor gene, whose mutation causes the hyperparathyroidism-jaw tumour syndrome. The disease is an autosomal dominant disorder characterised by the occurrence of parathyroid adenoma or carcinoma, fibro-osseous jaw tumours of the mandible or maxilla and renal neoplastic and non-neoplastic abnormalities, such as Wilms' tumour, hamartoma or cystic renal disease [1, 16, 20]. HRPT2 gene is located in human chromosome 1q31.2, consists of 17 exons and spans 18.5 kb in the genome. It encodes a 2.7-kb transcript which is translated into a 531-amino-acid parafibromin protein with a molecular weight of 60 kd [3, 4, 23]. The 200-amino-acid C-terminal segment of parafibromin shares 32% identity and 54% homology with cell division cycle 73, a Saccharomyces cerevisiae protein forming the polymerase-associated factor 1 (Paf1) complex, which is associated with ribonucleic acid (RNA) polymerase II and involved in transcript site selection, transcriptional elongation, histone H2B ubiquitination, histone H3 methylation, poly (A) length control and coupling of transcriptional and posttranscriptional events [10, 17, 18, 24, 27]. Parafibromin overexpression was documented to inhibit colony formation and cellular proliferation and induce cell cycle arrest in the G1 phase, indicating that parafibromin has a critical role in cell growth [28]. Northern blot analysis showed HRPT2 expression in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas [4]. Western blot study revealed parafibromin expression as a 60-kd band in the adrenal gland, heart, pancreas and kidney but 40-kd immunoreactive bands in the heart and skeletal muscle of human [25]. Immunohistochemically, higher expression of parafibromin was found widespread in glomerular mesangial cell, hepatocytes, cells of the base of gastric glands, renal cortex tubules and the pars intermedia of the hypophysis [17]. Subsequent investigations have revealed that mutations in HRPT2 are present in 66-100% of sporadic parathyroid carcinomas [7, 20]. Hyperparathyroidism-jaw-tumours-syndrome-related and sporadic parathyroid carcinomas are characterised by loss of parafibromin nuclear immunoreactivity [5, 22]. Selvarajan et al. [19] found that parafibromin expression was inversely linked to tumour size, pathologic stage and lymphovascular invasion of breast carcinomas using immunohistochemistry in a tissue microarray (TMA) study. These findings suggested the potential roles of parafibromin in pathogenesis and progression of malignancies.
###end p 4
###begin p 5
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 1046 1054 <span type="species:ncbi:9606">patients</span>
Gastric carcinoma ranks as the world's second leading cause of cancer mortality behind lung cancer despite a sharp worldwide decline in both its incidence and mortality since the second half of the 20th century [9]. Tumourigenesis and progression of gastric carcinoma is a multistage process with the involvement of a multifactorial aetiology, which mainly results from gene-environment interactions [32, 33]. Gastric carcinomas are classified into early and advanced ones on the basis of whether the carcinomas invade into the muscularis propria of the stomach [12]. In 1965, Lauren [13] classified gastric carcinomas into intestinal- and diffuse-type ones based on the morphological appearances. Intestinal-type carcinomas are characterised by cohesive carcinoma cells forming gland-like tubular structures with expanding or infiltrative growth pattern. However, the cell cohesion is less apparent or absent in diffuse-type carcinoma and cancer cells diffusely spread in the gastric wall [31]. Generally, there is a favorable prognosis for the patients with early or intestinal carcinoma compared with the other type. In our study, parafibromin expression was examined in gastric carcinoma, adenoma, gastritis and gastric carcinoma cell lines and compared with the clinicopathological parametres of carcinomas, as well as prognosis to explore the clinicopathological significance and molecular roles of parafibromin expression in stepwise development of gastric carcinoma.
###end p 5
###begin title 6
Materials and methods
###end title 6
###begin title 7
Subjects
###end title 7
###begin p 8
###xml 20 21 20 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 143 144 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
###xml 484 487 <span type="species:ncbi:9606">men</span>
###xml 496 501 <span type="species:ncbi:9606">women</span>
###xml 626 634 <span type="species:ncbi:9606">patients</span>
###xml 851 859 <span type="species:ncbi:9606">patients</span>
Gastric carcinomas (n = 508) were collected from the surgical resection, adenoma (n = 45) from endoscopic biopsy or polypectomy and gastritis (n = 49) from the endoscopic biopsy in our affiliated hospital, Himi Citizen Hospital and Kouseiren Takanoka Hospital between 1993 and 2006. All carcinomas were adenocarcinomas and the adenoma group was free from non-neoplastic polyp types, leiomyomas and benign gastrointestinal stromal tumours. The patients with gastric carcinoma were 354 men and 154 women (29~91 years, mean = 65.4 years). Among them, 191 cases have carcinomas accompanied with lymph node metastasis. None of the patients underwent chemotherapy or radiotherapy before surgery. They all provided consent for use of tumour tissue for clinical research and our University Ethical Committee approved the research protocol. We followed up all patients by consulting their case documents or through telephone.
###end p 8
###begin title 9
Pathology
###end title 9
###begin p 10
###xml 402 404 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 490 492 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 494 496 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
All tissues were fixed in 4% neutralised formaldehyde, embedded in paraffin and incised into 4-mum sections. These sections were stained by haematoxylin and eosin (HE) to confirm their histological diagnosis and other microscopic characteristics. The staging for each gastric carcinoma was evaluated according to the Union Internationale Contre le Cancer (UICC) system for the extent of tumour spread [21]. Histological architecture of gastric carcinoma was expressed in terms of Lauren's [13, 31] classification. Furthermore, tumour size, depth of invasion, lymphatic and venous invasion were determined.
###end p 10
###begin title 11
Tissue microarray
###end title 11
###begin p 12
Representative areas of solid tumours were identified in HE-stained sections of the selected tumour cases and a 2-mm-in-diametre tissue core per donor block was punched out and transferred to a recipient block with a maximum of 48 cores using a Tissue Microarrayer (AZUMAYA KIN-1, Japan). Four-micrometre-thick sections were consecutively incised from the recipient block and transferred to polylysine-coated glass slides. HE staining was performed on TMA for confirmation of tumour tissue.
###end p 12
###begin title 13
Cell lines and culture
###end title 13
###begin p 14
###xml 601 602 600 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 499 505 <span type="species:ncbi:9913">bovine</span>
Gastric carcinoma cell lines come from the Japanese Physical and Chemical Institute, including MKN28 (well-differentiated adenocarcinoma), AGS (moderately differentiated adenocarcinoma), MNK45 (poorly differentiated adenocarcinoma), KATO-III (poorly differentiated adenocarcinoma) and HGC-27 (undifferentiated adenocarcinoma). They were maintained in Roswell Park Memorial Institute 1640 (MKN28, MKN45 and KATO-III), minimum essential (HGC-27) or Ham's F12 (AGS) medium supplemented with 10% foetal bovine serum, 100-units/ml penicillin, and 100-mug/ml streptomycin in a humidified atmosphere of 5% CO2 at 37degreesC. Total protein was prepared from all cells by cell disruption buffer according to Protein And RNA Isolation System manual (Arctiris Bioscience, USA). All cells were collected by centrifugation, rinsed with phosphate-buffered saline, fixed by 10% formalin and then embedded in paraffin as routinely processed.
###end p 14
###begin title 15
Immunohistochemistry
###end title 15
###begin p 16
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 297 303 <span type="species:ncbi:9913">bovine</span>
###xml 411 416 <span type="species:ncbi:10090">mouse</span>
###xml 532 537 <span type="species:ncbi:10090">mouse</span>
Consecutive sections were deparaffinised with xylene, dehydrated with alcohol and subjected to antigen retrieval by irradiating in target retrieval solution citrate pH 6.0 (TRS, DAKO, Carpinteria, CA 93013, USA) for 15 min with microwave oven (Oriental Rotor Lmt. Co., Tokyo, Japan). Five percent bovine serum albumin was then applied for 1 min to prevent non-specific binding. The sections were incubated with mouse anti-parafibromin antibody (Clone 2H1, SC-33638, Santa Cruz, CA, USA; 1:40) for 15 min, then treated with the anti-mouse Envison-PO (DAKO, CA, USA) antibody for 15 min. Binding sites were visualised with 3, 3'-diaminobenzidine with the 5-min reaction. All the incubations were performed in a microwave oven to allow intermittent irradiation as described previously [11]. After each treatment, the slides were washed with Tris-buffered saline with Tween 20 (TBST; 10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20) three times for 1 min. After being counterstained with Mayer's haematoxylin, the sections were dehydrated, cleared and mounted. Omission of the primary antibody was used as a negative control.
###end p 16
###begin p 17
One hundred cells were randomly selected and counted from five representative fields of each section blindly by three independent observers (Takano Y, Li XH and Zheng HC). The positive percentage of counted cells was graded semi-quantitatively according to a four-tier scoring system: negative (-), 0~5%; weakly positive (+), 6~25%; moderately positive (++), 26~50%; and strongly positive (+++), 51~100%.
###end p 17
###begin title 18
Western blot
###end title 18
###begin p 19
###xml 265 270 <span type="species:ncbi:10090">mouse</span>
###xml 370 375 <span type="species:ncbi:10090">mouse</span>
###xml 407 418 <span type="species:ncbi:3704">horseradish</span>
###xml 712 717 <span type="species:ncbi:10090">mouse</span>
Fifty-microgramme denatured protein was separated on an SDS-polyacrylamide gel (10% acrylamide) and transferred to Hybond membrane (Amersham, Germany), which was then blocked overnight in 5% milk in TBST. For immunoblotting, the membrane was incubated for 1 h with mouse anti-parafibromin antibody as described above. Then, it was rinsed by TBST and incubated with anti-mouse immunoglobulin G conjugated to horseradish peroxidase (DAKO, CA, USA, 1:1,000) for 1 h. Bands were visualised with X-ray film (Fujifilm, Japan) by ECL-Plus detection reagents (Amersham, Germany). After that, membrane was washed with WB Stripping Solution (pH 2-3, Nacalai, Tokyo, Japan) for 30 min and treated as described above except mouse anti-beta-actin antibody (Sigma, MO, USA, 1:5,000) as an internal control.
###end p 19
###begin title 20
Statistical analysis
###end title 20
###begin p 21
###xml 43 51 43 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Spearman</italic>
###xml 95 101 95 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kaplan</italic>
###xml 102 107 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Meier</italic>
###xml 294 295 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Statistical evaluation was performed using Spearman correlation test to analyse the rank data. Kaplan-Meier survival plots were generated and comparisons between survival curves were made with the log-rank statistic. The Cox's proportional hazards model was employed for multivariate analysis. P < 0.05 was considered as statistically significant. SPSS 10.0 software was employed to analyse all data.
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
Parafibromin expression in gastric tumours and carcinoma cell lines
###end title 23
###begin p 24
###xml 17 18 17 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 888 889 888 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 904 905 904 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 931 932 931 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1080 1081 1080 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1127 1128 1127 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1230 1231 1230 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1343 1344 1343 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1354 1360 1354 1360 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1417 1418 1417 1418 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1486 1487 1486 1487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 1495 1496 1495 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 1506 1507 1506 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1520 1521 1520 1521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1534 1535 1534 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 1538 1539 1538 1539 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1680 1687 1673 1680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane #1</italic>
###xml 1696 1698 1689 1691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">#2</italic>
###xml 1704 1706 1697 1699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">#3</italic>
###xml 1714 1716 1707 1709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">#4</italic>
###xml 1727 1729 1720 1722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">#5</italic>
###xml 1360 1736 1360 1729 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25">Parafibromin expression in gastric carcinoma cell lines. <bold>a</bold> Parafibromin was positively immunostained in the nucleus of MKN28 (<italic>a</italic>), AGS (<italic>b</italic>), MKN45 (<italic>c</italic>), KATO-III (<italic>d</italic>) and HGC-27(<italic>e</italic>). <bold>b</bold> Cell lysate (50&#160;&#181;g) was loaded and probed with anti-human parafibromin antibody (60&#160;kd) with &#946;-actin (42&#160;kd) as an internal control. <italic>Lane #1</italic>: MKN28; <italic>#2</italic> AGS; <italic>#3</italic> MKN45; <italic>#4</italic> KATO-III; <italic>#5</italic> HGC-27</p>
###xml 1360 1736 1360 1729 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25">Parafibromin expression in gastric carcinoma cell lines. <bold>a</bold> Parafibromin was positively immunostained in the nucleus of MKN28 (<italic>a</italic>), AGS (<italic>b</italic>), MKN45 (<italic>c</italic>), KATO-III (<italic>d</italic>) and HGC-27(<italic>e</italic>). <bold>b</bold> Cell lysate (50&#160;&#181;g) was loaded and probed with anti-human parafibromin antibody (60&#160;kd) with &#946;-actin (42&#160;kd) as an internal control. <italic>Lane #1</italic>: MKN28; <italic>#2</italic> AGS; <italic>#3</italic> MKN45; <italic>#4</italic> KATO-III; <italic>#5</italic> HGC-27</p></caption>
###xml 1736 1736 1729 1729 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="428_2007_551_Fig1_HTML" id="MO1"/>
###xml 1354 1736 1354 1729 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="25">Parafibromin expression in gastric carcinoma cell lines. <bold>a</bold> Parafibromin was positively immunostained in the nucleus of MKN28 (<italic>a</italic>), AGS (<italic>b</italic>), MKN45 (<italic>c</italic>), KATO-III (<italic>d</italic>) and HGC-27(<italic>e</italic>). <bold>b</bold> Cell lysate (50&#160;&#181;g) was loaded and probed with anti-human parafibromin antibody (60&#160;kd) with &#946;-actin (42&#160;kd) as an internal control. <italic>Lane #1</italic>: MKN28; <italic>#2</italic> AGS; <italic>#3</italic> MKN45; <italic>#4</italic> KATO-III; <italic>#5</italic> HGC-27</p></caption><graphic position="anchor" xlink:href="428_2007_551_Fig1_HTML" id="MO1"/></fig>
###xml 1736 1742 1729 1735 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1925 1926 1918 1919 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1942 1943 1935 1936 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1974 1975 1967 1968 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2041 2042 2034 2035 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2044 2045 2037 2038 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2094 2095 2087 2088 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1742 2277 1735 2270 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">Immunohistochemical staining of parafibromin in gastritis, adenoma and carcinoma. Note parafibromin positivity was strongly observed in the nucleus of gastric superficial epithelium (<bold>a</bold>), and adenoma (<bold>c</bold>) and early gastric carcinoma (<bold>b</bold>), occasionally weaker in the stromal fibroblasts and lymphocytes(<bold>a</bold>, <bold>c</bold>), but not in given advanced gastric carcinomas (<bold>d</bold>), indicating that the internal positive control (stromal cells) was negative adjacent to the negative staining carcinoma cells but positive adjacent to the positive epithelial cells</p>
###xml 1742 2277 1735 2270 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">Immunohistochemical staining of parafibromin in gastritis, adenoma and carcinoma. Note parafibromin positivity was strongly observed in the nucleus of gastric superficial epithelium (<bold>a</bold>), and adenoma (<bold>c</bold>) and early gastric carcinoma (<bold>b</bold>), occasionally weaker in the stromal fibroblasts and lymphocytes(<bold>a</bold>, <bold>c</bold>), but not in given advanced gastric carcinomas (<bold>d</bold>), indicating that the internal positive control (stromal cells) was negative adjacent to the negative staining carcinoma cells but positive adjacent to the positive epithelial cells</p></caption>
###xml 2277 2277 2270 2270 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="428_2007_551_Fig2_HTML" id="MO2"/>
###xml 1736 2277 1729 2270 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="26">Immunohistochemical staining of parafibromin in gastritis, adenoma and carcinoma. Note parafibromin positivity was strongly observed in the nucleus of gastric superficial epithelium (<bold>a</bold>), and adenoma (<bold>c</bold>) and early gastric carcinoma (<bold>b</bold>), occasionally weaker in the stromal fibroblasts and lymphocytes(<bold>a</bold>, <bold>c</bold>), but not in given advanced gastric carcinomas (<bold>d</bold>), indicating that the internal positive control (stromal cells) was negative adjacent to the negative staining carcinoma cells but positive adjacent to the positive epithelial cells</p></caption><graphic position="anchor" xlink:href="428_2007_551_Fig2_HTML" id="MO2"/></fig>
###xml 2277 2284 2270 2277 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 2284 2333 2277 2326 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">Parafibromin expression in gastric tissue samples</p>
###xml 2284 2333 2277 2326 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">Parafibromin expression in gastric tissue samples</p></caption>
###xml 2333 2339 2326 2332 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Groups</th>
###xml 2339 2345 2332 2338 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Number</th>
###xml 2345 2368 2338 2361 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Parafibromin expression</th>
###xml 2333 2368 2326 2361 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Groups</th><th rowspan="2">Number</th><th align="left" colspan="5">Parafibromin expression</th></tr>
###xml 2368 2369 2361 2362 <th xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</th>
###xml 2369 2370 2362 2363 <th xmlns:xlink="http://www.w3.org/1999/xlink">+</th>
###xml 2370 2372 2363 2365 <th xmlns:xlink="http://www.w3.org/1999/xlink">++</th>
###xml 2372 2375 2365 2368 <th xmlns:xlink="http://www.w3.org/1999/xlink">+++</th>
###xml 2375 2381 2368 2374 <th xmlns:xlink="http://www.w3.org/1999/xlink">PR (%)</th>
###xml 2368 2381 2361 2374 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>&#8722;</th><th>+</th><th>++</th><th>+++</th><th>PR (%)</th></tr>
###xml 2333 2381 2326 2374 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Groups</th><th rowspan="2">Number</th><th align="left" colspan="5">Parafibromin expression</th></tr><tr><th>&#8722;</th><th>+</th><th>++</th><th>+++</th><th>PR (%)</th></tr></thead>
###xml 2381 2390 2374 2383 <td xmlns:xlink="http://www.w3.org/1999/xlink">Gastritis</td>
###xml 2390 2392 2383 2385 <td xmlns:xlink="http://www.w3.org/1999/xlink">49</td>
###xml 2392 2393 2385 2386 <td xmlns:xlink="http://www.w3.org/1999/xlink">0</td>
###xml 2393 2394 2386 2387 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 2394 2395 2387 2388 <td xmlns:xlink="http://www.w3.org/1999/xlink">7</td>
###xml 2395 2397 2388 2390 <td xmlns:xlink="http://www.w3.org/1999/xlink">41</td>
###xml 2402 2403 2395 2396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2397 2403 2390 2396 <td xmlns:xlink="http://www.w3.org/1999/xlink">100.0<sup>a</sup></td>
###xml 2381 2403 2374 2396 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Gastritis</td><td>49</td><td>0</td><td>1</td><td>7</td><td>41</td><td>100.0<sup>a</sup></td></tr>
###xml 2403 2418 2396 2411 <td xmlns:xlink="http://www.w3.org/1999/xlink">Gastric adenoma</td>
###xml 2418 2420 2411 2413 <td xmlns:xlink="http://www.w3.org/1999/xlink">45</td>
###xml 2420 2421 2413 2414 <td xmlns:xlink="http://www.w3.org/1999/xlink">9</td>
###xml 2421 2422 2414 2415 <td xmlns:xlink="http://www.w3.org/1999/xlink">5</td>
###xml 2422 2423 2415 2416 <td xmlns:xlink="http://www.w3.org/1999/xlink">8</td>
###xml 2423 2425 2416 2418 <td xmlns:xlink="http://www.w3.org/1999/xlink">23</td>
###xml 2429 2430 2422 2423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2425 2430 2418 2423 <td xmlns:xlink="http://www.w3.org/1999/xlink">80.0<sup>b</sup></td>
###xml 2403 2430 2396 2423 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Gastric adenoma</td><td>45</td><td>9</td><td>5</td><td>8</td><td>23</td><td>80.0<sup>b</sup></td></tr>
###xml 2430 2447 2423 2440 <td xmlns:xlink="http://www.w3.org/1999/xlink">Gastric carcinoma</td>
###xml 2447 2450 2440 2443 <td xmlns:xlink="http://www.w3.org/1999/xlink">508</td>
###xml 2450 2453 2443 2446 <td xmlns:xlink="http://www.w3.org/1999/xlink">275</td>
###xml 2453 2455 2446 2448 <td xmlns:xlink="http://www.w3.org/1999/xlink">55</td>
###xml 2455 2457 2448 2450 <td xmlns:xlink="http://www.w3.org/1999/xlink">60</td>
###xml 2457 2460 2450 2453 <td xmlns:xlink="http://www.w3.org/1999/xlink">118</td>
###xml 2460 2464 2453 2457 <td xmlns:xlink="http://www.w3.org/1999/xlink">45.9</td>
###xml 2430 2464 2423 2457 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Gastric carcinoma</td><td>508</td><td>275</td><td>55</td><td>60</td><td>118</td><td>45.9</td></tr>
###xml 2381 2464 2374 2457 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Gastritis</td><td>49</td><td>0</td><td>1</td><td>7</td><td>41</td><td>100.0<sup>a</sup></td></tr><tr><td>Gastric adenoma</td><td>45</td><td>9</td><td>5</td><td>8</td><td>23</td><td>80.0<sup>b</sup></td></tr><tr><td>Gastric carcinoma</td><td>508</td><td>275</td><td>55</td><td>60</td><td>118</td><td>45.9</td></tr></tbody>
###xml 2333 2464 2326 2457 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Groups</th><th rowspan="2">Number</th><th align="left" colspan="5">Parafibromin expression</th></tr><tr><th>&#8722;</th><th>+</th><th>++</th><th>+++</th><th>PR (%)</th></tr></thead><tbody><tr><td>Gastritis</td><td>49</td><td>0</td><td>1</td><td>7</td><td>41</td><td>100.0<sup>a</sup></td></tr><tr><td>Gastric adenoma</td><td>45</td><td>9</td><td>5</td><td>8</td><td>23</td><td>80.0<sup>b</sup></td></tr><tr><td>Gastric carcinoma</td><td>508</td><td>275</td><td>55</td><td>60</td><td>118</td><td>45.9</td></tr></tbody></table>
###xml 2464 2466 2457 2459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PR</italic>
###xml 2464 2480 2457 2473 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><italic>PR</italic> Positive rate</p>
###xml 2480 2481 2473 2474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2525 2526 2518 2519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2480 2534 2473 2527 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29"><sup>a</sup>Compared with gastric adenoma or carcinoma, <italic>p</italic>&#8201;&lt;&#8201;0.001</p>
###xml 2534 2535 2527 2528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2568 2569 2561 2562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2534 2577 2527 2570 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30"><sup>b</sup>Compared with gastric carcinoma, <italic>p</italic>&#8201;&lt;&#8201;0.001</p>
###xml 2464 2577 2457 2570 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28"><italic>PR</italic> Positive rate</p><p textid="29"><sup>a</sup>Compared with gastric adenoma or carcinoma, <italic>p</italic>&#8201;&lt;&#8201;0.001</p><p textid="30"><sup>b</sup>Compared with gastric carcinoma, <italic>p</italic>&#8201;&lt;&#8201;0.001</p></table-wrap-foot>
###xml 2277 2577 2270 2570 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="27">Parafibromin expression in gastric tissue samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Groups</th><th rowspan="2">Number</th><th align="left" colspan="5">Parafibromin expression</th></tr><tr><th>&#8722;</th><th>+</th><th>++</th><th>+++</th><th>PR (%)</th></tr></thead><tbody><tr><td>Gastritis</td><td>49</td><td>0</td><td>1</td><td>7</td><td>41</td><td>100.0<sup>a</sup></td></tr><tr><td>Gastric adenoma</td><td>45</td><td>9</td><td>5</td><td>8</td><td>23</td><td>80.0<sup>b</sup></td></tr><tr><td>Gastric carcinoma</td><td>508</td><td>275</td><td>55</td><td>60</td><td>118</td><td>45.9</td></tr></tbody></table><table-wrap-foot><p textid="28"><italic>PR</italic> Positive rate</p><p textid="29"><sup>a</sup>Compared with gastric adenoma or carcinoma, <italic>p</italic>&#8201;&lt;&#8201;0.001</p><p textid="30"><sup>b</sup>Compared with gastric carcinoma, <italic>p</italic>&#8201;&lt;&#8201;0.001</p></table-wrap-foot></table-wrap>
###xml 2577 2584 2570 2577 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 2584 2684 2577 2677 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31"> Relationship between parafibromin expression and clinicopathological features of gastric carcinomas</p>
###xml 2584 2684 2577 2677 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31"> Relationship between parafibromin expression and clinicopathological features of gastric carcinomas</p></caption>
###xml 2684 2712 2677 2705 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Clinicopathological features</th>
###xml 2712 2718 2705 2711 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Number</th>
###xml 2718 2741 2711 2734 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="7">Parafibromin expression</th>
###xml 2684 2741 2677 2734 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Clinicopathological features</th><th rowspan="2">Number</th><th align="left" colspan="7">Parafibromin expression</th></tr>
###xml 2741 2742 2734 2735 <th xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</th>
###xml 2742 2743 2735 2736 <th xmlns:xlink="http://www.w3.org/1999/xlink">+</th>
###xml 2743 2745 2736 2738 <th xmlns:xlink="http://www.w3.org/1999/xlink">++</th>
###xml 2745 2748 2738 2741 <th xmlns:xlink="http://www.w3.org/1999/xlink">+++</th>
###xml 2748 2754 2741 2747 <th xmlns:xlink="http://www.w3.org/1999/xlink">PR (%)</th>
###xml 2754 2756 2747 2749 <th xmlns:xlink="http://www.w3.org/1999/xlink">Rs</th>
###xml 2756 2757 2749 2750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2756 2763 2749 2756 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 2741 2763 2734 2756 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>&#8722;</th><th>+</th><th>++</th><th>+++</th><th>PR (%)</th><th>Rs</th><th><italic>p</italic> value</th></tr>
###xml 2684 2763 2677 2756 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Clinicopathological features</th><th rowspan="2">Number</th><th align="left" colspan="7">Parafibromin expression</th></tr><tr><th>&#8722;</th><th>+</th><th>++</th><th>+++</th><th>PR (%)</th><th>Rs</th><th><italic>p</italic> value</th></tr></thead>
###xml 2763 2774 2756 2767 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">Age (years)</td>
###xml 2763 2774 2756 2767 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">Age (years)</td></tr>
###xml 2774 2779 2767 2772 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&lt;65</td>
###xml 2779 2782 2772 2775 <td xmlns:xlink="http://www.w3.org/1999/xlink">209</td>
###xml 2782 2785 2775 2778 <td xmlns:xlink="http://www.w3.org/1999/xlink">125</td>
###xml 2785 2787 2778 2780 <td xmlns:xlink="http://www.w3.org/1999/xlink">24</td>
###xml 2787 2789 2780 2782 <td xmlns:xlink="http://www.w3.org/1999/xlink">24</td>
###xml 2789 2791 2782 2784 <td xmlns:xlink="http://www.w3.org/1999/xlink">36</td>
###xml 2791 2795 2784 2788 <td xmlns:xlink="http://www.w3.org/1999/xlink">40.2</td>
###xml 2795 2800 2788 2793 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">0.095</td>
###xml 2800 2805 2793 2798 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&lt;0.05</td>
###xml 2774 2805 2767 2798 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&lt;65</td><td>209</td><td>125</td><td>24</td><td>24</td><td>36</td><td>40.2</td><td rowspan="2">0.095</td><td rowspan="2">&lt;0.05</td></tr>
###xml 2805 2812 2798 2803 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8805;65</td>
###xml 2812 2815 2803 2806 <td xmlns:xlink="http://www.w3.org/1999/xlink">299</td>
###xml 2815 2818 2806 2809 <td xmlns:xlink="http://www.w3.org/1999/xlink">150</td>
###xml 2818 2820 2809 2811 <td xmlns:xlink="http://www.w3.org/1999/xlink">31</td>
###xml 2820 2822 2811 2813 <td xmlns:xlink="http://www.w3.org/1999/xlink">36</td>
###xml 2822 2824 2813 2815 <td xmlns:xlink="http://www.w3.org/1999/xlink">82</td>
###xml 2824 2828 2815 2819 <td xmlns:xlink="http://www.w3.org/1999/xlink">49.8</td>
###xml 2805 2828 2798 2819 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8805;65</td><td>299</td><td>150</td><td>31</td><td>36</td><td>82</td><td>49.8</td></tr>
###xml 2828 2831 2819 2822 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">Sex</td>
###xml 2828 2831 2819 2822 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">Sex</td></tr>
###xml 2831 2837 2822 2828 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Male</td>
###xml 2837 2840 2828 2831 <td xmlns:xlink="http://www.w3.org/1999/xlink">354</td>
###xml 2840 2843 2831 2834 <td xmlns:xlink="http://www.w3.org/1999/xlink">188</td>
###xml 2843 2845 2834 2836 <td xmlns:xlink="http://www.w3.org/1999/xlink">37</td>
###xml 2845 2847 2836 2838 <td xmlns:xlink="http://www.w3.org/1999/xlink">38</td>
###xml 2847 2849 2838 2840 <td xmlns:xlink="http://www.w3.org/1999/xlink">91</td>
###xml 2849 2853 2840 2844 <td xmlns:xlink="http://www.w3.org/1999/xlink">46.9</td>
###xml 2853 2858 2844 2849 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">0.054</td>
###xml 2858 2863 2849 2854 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&gt;0.05</td>
###xml 2831 2863 2822 2854 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Male</td><td>354</td><td>188</td><td>37</td><td>38</td><td>91</td><td>46.9</td><td rowspan="2">0.054</td><td rowspan="2">&gt;0.05</td></tr>
###xml 2863 2871 2854 2862 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Female</td>
###xml 2871 2874 2862 2865 <td xmlns:xlink="http://www.w3.org/1999/xlink">154</td>
###xml 2874 2876 2865 2867 <td xmlns:xlink="http://www.w3.org/1999/xlink">87</td>
###xml 2876 2878 2867 2869 <td xmlns:xlink="http://www.w3.org/1999/xlink">18</td>
###xml 2878 2880 2869 2871 <td xmlns:xlink="http://www.w3.org/1999/xlink">22</td>
###xml 2880 2882 2871 2873 <td xmlns:xlink="http://www.w3.org/1999/xlink">27</td>
###xml 2882 2886 2873 2877 <td xmlns:xlink="http://www.w3.org/1999/xlink">43.5</td>
###xml 2863 2886 2854 2877 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Female</td><td>154</td><td>87</td><td>18</td><td>22</td><td>27</td><td>43.5</td></tr>
###xml 2886 2902 2877 2893 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">Tumour size (cm)</td>
###xml 2886 2902 2877 2893 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">Tumour size (cm)</td></tr>
###xml 2902 2906 2893 2897 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&lt;4</td>
###xml 2906 2909 2897 2900 <td xmlns:xlink="http://www.w3.org/1999/xlink">263</td>
###xml 2909 2912 2900 2903 <td xmlns:xlink="http://www.w3.org/1999/xlink">116</td>
###xml 2912 2914 2903 2905 <td xmlns:xlink="http://www.w3.org/1999/xlink">26</td>
###xml 2914 2916 2905 2907 <td xmlns:xlink="http://www.w3.org/1999/xlink">34</td>
###xml 2916 2918 2907 2909 <td xmlns:xlink="http://www.w3.org/1999/xlink">85</td>
###xml 2918 2922 2909 2913 <td xmlns:xlink="http://www.w3.org/1999/xlink">55.9</td>
###xml 2922 2928 2913 2919 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#8722;0.237</td>
###xml 2928 2934 2919 2925 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&lt;0.001</td>
###xml 2902 2934 2893 2925 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&lt;4</td><td>263</td><td>116</td><td>26</td><td>34</td><td>85</td><td>55.9</td><td rowspan="2">&#8722;0.237</td><td rowspan="2">&lt;0.001</td></tr>
###xml 2934 2940 2925 2929 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8805;4</td>
###xml 2940 2943 2929 2932 <td xmlns:xlink="http://www.w3.org/1999/xlink">245</td>
###xml 2943 2946 2932 2935 <td xmlns:xlink="http://www.w3.org/1999/xlink">159</td>
###xml 2946 2948 2935 2937 <td xmlns:xlink="http://www.w3.org/1999/xlink">27</td>
###xml 2948 2950 2937 2939 <td xmlns:xlink="http://www.w3.org/1999/xlink">26</td>
###xml 2950 2952 2939 2941 <td xmlns:xlink="http://www.w3.org/1999/xlink">33</td>
###xml 2952 2956 2941 2945 <td xmlns:xlink="http://www.w3.org/1999/xlink">35.1</td>
###xml 2934 2956 2925 2945 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8805;4</td><td>245</td><td>159</td><td>27</td><td>26</td><td>33</td><td>35.1</td></tr>
###xml 2956 2973 2945 2962 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">Depth of invasion</td>
###xml 2956 2973 2945 2962 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">Depth of invasion</td></tr>
###xml 2976 2980 2965 2969 <sub xmlns:xlink="http://www.w3.org/1999/xlink">is&#8722;1</sub>
###xml 2973 2980 2962 2969 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;T<sub>is&#8722;1</sub></td>
###xml 2980 2983 2969 2972 <td xmlns:xlink="http://www.w3.org/1999/xlink">263</td>
###xml 2983 2986 2972 2975 <td xmlns:xlink="http://www.w3.org/1999/xlink">102</td>
###xml 2986 2988 2975 2977 <td xmlns:xlink="http://www.w3.org/1999/xlink">30</td>
###xml 2988 2990 2977 2979 <td xmlns:xlink="http://www.w3.org/1999/xlink">40</td>
###xml 2990 2992 2979 2981 <td xmlns:xlink="http://www.w3.org/1999/xlink">91</td>
###xml 2992 2996 2981 2985 <td xmlns:xlink="http://www.w3.org/1999/xlink">61.2</td>
###xml 2996 3002 2985 2991 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#8722;0.344</td>
###xml 3002 3008 2991 2997 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&lt;0.001</td>
###xml 2973 3008 2962 2997 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;T<sub>is&#8722;1</sub></td><td>263</td><td>102</td><td>30</td><td>40</td><td>91</td><td>61.2</td><td rowspan="2">&#8722;0.344</td><td rowspan="2">&lt;0.001</td></tr>
###xml 3011 3014 3000 3003 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2-4</sub>
###xml 3008 3014 2997 3003 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;T<sub>2-4</sub></td>
###xml 3014 3017 3003 3006 <td xmlns:xlink="http://www.w3.org/1999/xlink">245</td>
###xml 3017 3020 3006 3009 <td xmlns:xlink="http://www.w3.org/1999/xlink">173</td>
###xml 3020 3022 3009 3011 <td xmlns:xlink="http://www.w3.org/1999/xlink">25</td>
###xml 3022 3024 3011 3013 <td xmlns:xlink="http://www.w3.org/1999/xlink">20</td>
###xml 3024 3026 3013 3015 <td xmlns:xlink="http://www.w3.org/1999/xlink">27</td>
###xml 3026 3030 3015 3019 <td xmlns:xlink="http://www.w3.org/1999/xlink">29.4</td>
###xml 3008 3030 2997 3019 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;T<sub>2-4</sub></td><td>245</td><td>173</td><td>25</td><td>20</td><td>27</td><td>29.4</td></tr>
###xml 3030 3048 3019 3037 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">Lymphatic invasion</td>
###xml 3030 3048 3019 3037 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">Lymphatic invasion</td></tr>
###xml 3048 3051 3037 3040 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8722;</td>
###xml 3051 3054 3040 3043 <td xmlns:xlink="http://www.w3.org/1999/xlink">331</td>
###xml 3054 3057 3043 3046 <td xmlns:xlink="http://www.w3.org/1999/xlink">157</td>
###xml 3057 3059 3046 3048 <td xmlns:xlink="http://www.w3.org/1999/xlink">42</td>
###xml 3059 3061 3048 3050 <td xmlns:xlink="http://www.w3.org/1999/xlink">45</td>
###xml 3061 3063 3050 3052 <td xmlns:xlink="http://www.w3.org/1999/xlink">87</td>
###xml 3063 3067 3052 3056 <td xmlns:xlink="http://www.w3.org/1999/xlink">52.6</td>
###xml 3067 3073 3056 3062 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#8722;0.168</td>
###xml 3073 3079 3062 3068 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&lt;0.001</td>
###xml 3048 3079 3037 3068 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8722;</td><td>331</td><td>157</td><td>42</td><td>45</td><td>87</td><td>52.6</td><td rowspan="2">&#8722;0.168</td><td rowspan="2">&lt;0.001</td></tr>
###xml 3079 3082 3068 3071 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;+</td>
###xml 3082 3085 3071 3074 <td xmlns:xlink="http://www.w3.org/1999/xlink">177</td>
###xml 3085 3088 3074 3077 <td xmlns:xlink="http://www.w3.org/1999/xlink">118</td>
###xml 3088 3090 3077 3079 <td xmlns:xlink="http://www.w3.org/1999/xlink">13</td>
###xml 3090 3092 3079 3081 <td xmlns:xlink="http://www.w3.org/1999/xlink">15</td>
###xml 3092 3094 3081 3083 <td xmlns:xlink="http://www.w3.org/1999/xlink">31</td>
###xml 3094 3098 3083 3087 <td xmlns:xlink="http://www.w3.org/1999/xlink">33.3</td>
###xml 3079 3098 3068 3087 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;+</td><td>177</td><td>118</td><td>13</td><td>15</td><td>31</td><td>33.3</td></tr>
###xml 3098 3113 3087 3102 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">Venous invasion</td>
###xml 3098 3113 3087 3102 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">Venous invasion</td></tr>
###xml 3113 3116 3102 3105 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8722;</td>
###xml 3116 3119 3105 3108 <td xmlns:xlink="http://www.w3.org/1999/xlink">443</td>
###xml 3119 3122 3108 3111 <td xmlns:xlink="http://www.w3.org/1999/xlink">236</td>
###xml 3122 3124 3111 3113 <td xmlns:xlink="http://www.w3.org/1999/xlink">49</td>
###xml 3124 3126 3113 3115 <td xmlns:xlink="http://www.w3.org/1999/xlink">51</td>
###xml 3126 3129 3115 3118 <td xmlns:xlink="http://www.w3.org/1999/xlink">107</td>
###xml 3129 3133 3118 3122 <td xmlns:xlink="http://www.w3.org/1999/xlink">46.7</td>
###xml 3133 3139 3122 3128 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#8722;0.051</td>
###xml 3139 3144 3128 3133 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&gt;0.05</td>
###xml 3113 3144 3102 3133 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8722;</td><td>443</td><td>236</td><td>49</td><td>51</td><td>107</td><td>46.7</td><td rowspan="2">&#8722;0.051</td><td rowspan="2">&gt;0.05</td></tr>
###xml 3144 3147 3133 3136 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;+</td>
###xml 3147 3149 3136 3138 <td xmlns:xlink="http://www.w3.org/1999/xlink">65</td>
###xml 3149 3151 3138 3140 <td xmlns:xlink="http://www.w3.org/1999/xlink">39</td>
###xml 3151 3152 3140 3141 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 3152 3153 3141 3142 <td xmlns:xlink="http://www.w3.org/1999/xlink">9</td>
###xml 3153 3155 3142 3144 <td xmlns:xlink="http://www.w3.org/1999/xlink">11</td>
###xml 3155 3159 3144 3148 <td xmlns:xlink="http://www.w3.org/1999/xlink">40.0</td>
###xml 3144 3159 3133 3148 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;+</td><td>65</td><td>39</td><td>6</td><td>9</td><td>11</td><td>40.0</td></tr>
###xml 3159 3180 3148 3169 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">Lymph node metastasis</td>
###xml 3159 3180 3148 3169 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">Lymph node metastasis</td></tr>
###xml 3180 3183 3169 3172 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;&#8722;</td>
###xml 3183 3186 3172 3175 <td xmlns:xlink="http://www.w3.org/1999/xlink">317</td>
###xml 3186 3189 3175 3178 <td xmlns:xlink="http://www.w3.org/1999/xlink">138</td>
###xml 3189 3191 3178 3180 <td xmlns:xlink="http://www.w3.org/1999/xlink">38</td>
###xml 3191 3193 3180 3182 <td xmlns:xlink="http://www.w3.org/1999/xlink">44</td>
###xml 3193 3195 3182 3184 <td xmlns:xlink="http://www.w3.org/1999/xlink">97</td>
###xml 3195 3199 3184 3188 <td xmlns:xlink="http://www.w3.org/1999/xlink">56.5</td>
###xml 3199 3205 3188 3194 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#8722;0.285</td>
###xml 3205 3211 3194 3200 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&lt;0.001</td>
###xml 3180 3211 3169 3200 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;&#8722;</td><td>317</td><td>138</td><td>38</td><td>44</td><td>97</td><td>56.5</td><td rowspan="2">&#8722;0.285</td><td rowspan="2">&lt;0.001</td></tr>
###xml 3211 3214 3200 3203 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;+</td>
###xml 3214 3217 3203 3206 <td xmlns:xlink="http://www.w3.org/1999/xlink">191</td>
###xml 3217 3220 3206 3209 <td xmlns:xlink="http://www.w3.org/1999/xlink">137</td>
###xml 3220 3222 3209 3211 <td xmlns:xlink="http://www.w3.org/1999/xlink">17</td>
###xml 3222 3224 3211 3213 <td xmlns:xlink="http://www.w3.org/1999/xlink">16</td>
###xml 3224 3226 3213 3215 <td xmlns:xlink="http://www.w3.org/1999/xlink">21</td>
###xml 3226 3230 3215 3219 <td xmlns:xlink="http://www.w3.org/1999/xlink">28.3</td>
###xml 3211 3230 3200 3219 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;+</td><td>191</td><td>137</td><td>17</td><td>16</td><td>21</td><td>28.3</td></tr>
###xml 3230 3242 3219 3231 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">UICC staging</td>
###xml 3230 3242 3219 3231 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">UICC staging</td></tr>
###xml 3242 3247 3231 3236 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;0&#8211;I</td>
###xml 3247 3250 3236 3239 <td xmlns:xlink="http://www.w3.org/1999/xlink">292</td>
###xml 3250 3253 3239 3242 <td xmlns:xlink="http://www.w3.org/1999/xlink">123</td>
###xml 3253 3255 3242 3244 <td xmlns:xlink="http://www.w3.org/1999/xlink">36</td>
###xml 3255 3257 3244 3246 <td xmlns:xlink="http://www.w3.org/1999/xlink">41</td>
###xml 3257 3259 3246 3248 <td xmlns:xlink="http://www.w3.org/1999/xlink">92</td>
###xml 3259 3263 3248 3252 <td xmlns:xlink="http://www.w3.org/1999/xlink">57.9</td>
###xml 3263 3269 3252 3258 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#8722;0.292</td>
###xml 3269 3275 3258 3264 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&lt;0.001</td>
###xml 3242 3275 3231 3264 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;0&#8211;I</td><td>292</td><td>123</td><td>36</td><td>41</td><td>92</td><td>57.9</td><td rowspan="2">&#8722;0.292</td><td rowspan="2">&lt;0.001</td></tr>
###xml 3275 3282 3264 3271 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;II-IV</td>
###xml 3282 3285 3271 3274 <td xmlns:xlink="http://www.w3.org/1999/xlink">216</td>
###xml 3285 3288 3274 3277 <td xmlns:xlink="http://www.w3.org/1999/xlink">152</td>
###xml 3288 3290 3277 3279 <td xmlns:xlink="http://www.w3.org/1999/xlink">19</td>
###xml 3290 3292 3279 3281 <td xmlns:xlink="http://www.w3.org/1999/xlink">19</td>
###xml 3292 3294 3281 3283 <td xmlns:xlink="http://www.w3.org/1999/xlink">26</td>
###xml 3294 3298 3283 3287 <td xmlns:xlink="http://www.w3.org/1999/xlink">29.6</td>
###xml 3275 3298 3264 3287 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;II-IV</td><td>216</td><td>152</td><td>19</td><td>19</td><td>26</td><td>29.6</td></tr>
###xml 3298 3321 3287 3310 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">Lauren&#8217;s classification</td>
###xml 3298 3321 3287 3310 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">Lauren&#8217;s classification</td></tr>
###xml 3321 3338 3310 3327 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Intestinal-type</td>
###xml 3338 3341 3327 3330 <td xmlns:xlink="http://www.w3.org/1999/xlink">273</td>
###xml 3341 3344 3330 3333 <td xmlns:xlink="http://www.w3.org/1999/xlink">108</td>
###xml 3344 3346 3333 3335 <td xmlns:xlink="http://www.w3.org/1999/xlink">34</td>
###xml 3346 3348 3335 3337 <td xmlns:xlink="http://www.w3.org/1999/xlink">38</td>
###xml 3348 3350 3337 3339 <td xmlns:xlink="http://www.w3.org/1999/xlink">93</td>
###xml 3350 3354 3339 3343 <td xmlns:xlink="http://www.w3.org/1999/xlink">60.4</td>
###xml 3354 3360 3343 3349 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#8722;0.322</td>
###xml 3360 3366 3349 3355 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&lt;0.001</td>
###xml 3321 3366 3310 3355 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Intestinal-type</td><td>273</td><td>108</td><td>34</td><td>38</td><td>93</td><td>60.4</td><td rowspan="2">&#8722;0.322</td><td rowspan="2">&lt;0.001</td></tr>
###xml 3366 3380 3355 3369 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;&#160;Diffuse-type</td>
###xml 3380 3383 3369 3372 <td xmlns:xlink="http://www.w3.org/1999/xlink">225</td>
###xml 3383 3386 3372 3375 <td xmlns:xlink="http://www.w3.org/1999/xlink">157</td>
###xml 3386 3388 3375 3377 <td xmlns:xlink="http://www.w3.org/1999/xlink">21</td>
###xml 3388 3390 3377 3379 <td xmlns:xlink="http://www.w3.org/1999/xlink">22</td>
###xml 3390 3392 3379 3381 <td xmlns:xlink="http://www.w3.org/1999/xlink">25</td>
###xml 3392 3396 3381 3385 <td xmlns:xlink="http://www.w3.org/1999/xlink">30.2</td>
###xml 3366 3396 3355 3385 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;&#160;Diffuse-type</td><td>225</td><td>157</td><td>21</td><td>22</td><td>25</td><td>30.2</td></tr>
###xml 2763 3396 2756 3385 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="9">Age (years)</td></tr><tr><td>&#160;&#160;&lt;65</td><td>209</td><td>125</td><td>24</td><td>24</td><td>36</td><td>40.2</td><td rowspan="2">0.095</td><td rowspan="2">&lt;0.05</td></tr><tr><td>&#160;&#160;&#8805;65</td><td>299</td><td>150</td><td>31</td><td>36</td><td>82</td><td>49.8</td></tr><tr><td colspan="9">Sex</td></tr><tr><td>&#160;&#160;Male</td><td>354</td><td>188</td><td>37</td><td>38</td><td>91</td><td>46.9</td><td rowspan="2">0.054</td><td rowspan="2">&gt;0.05</td></tr><tr><td>&#160;&#160;Female</td><td>154</td><td>87</td><td>18</td><td>22</td><td>27</td><td>43.5</td></tr><tr><td colspan="9">Tumour size (cm)</td></tr><tr><td>&#160;&#160;&lt;4</td><td>263</td><td>116</td><td>26</td><td>34</td><td>85</td><td>55.9</td><td rowspan="2">&#8722;0.237</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;&#8805;4</td><td>245</td><td>159</td><td>27</td><td>26</td><td>33</td><td>35.1</td></tr><tr><td colspan="9">Depth of invasion</td></tr><tr><td>&#160;&#160;T<sub>is&#8722;1</sub></td><td>263</td><td>102</td><td>30</td><td>40</td><td>91</td><td>61.2</td><td rowspan="2">&#8722;0.344</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;T<sub>2-4</sub></td><td>245</td><td>173</td><td>25</td><td>20</td><td>27</td><td>29.4</td></tr><tr><td colspan="9">Lymphatic invasion</td></tr><tr><td>&#160;&#160;&#8722;</td><td>331</td><td>157</td><td>42</td><td>45</td><td>87</td><td>52.6</td><td rowspan="2">&#8722;0.168</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;+</td><td>177</td><td>118</td><td>13</td><td>15</td><td>31</td><td>33.3</td></tr><tr><td colspan="9">Venous invasion</td></tr><tr><td>&#160;&#160;&#8722;</td><td>443</td><td>236</td><td>49</td><td>51</td><td>107</td><td>46.7</td><td rowspan="2">&#8722;0.051</td><td rowspan="2">&gt;0.05</td></tr><tr><td>&#160;&#160;+</td><td>65</td><td>39</td><td>6</td><td>9</td><td>11</td><td>40.0</td></tr><tr><td colspan="9">Lymph node metastasis</td></tr><tr><td>&#160;&#160;&#8722;</td><td>317</td><td>138</td><td>38</td><td>44</td><td>97</td><td>56.5</td><td rowspan="2">&#8722;0.285</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;+</td><td>191</td><td>137</td><td>17</td><td>16</td><td>21</td><td>28.3</td></tr><tr><td colspan="9">UICC staging</td></tr><tr><td>&#160;&#160;0&#8211;I</td><td>292</td><td>123</td><td>36</td><td>41</td><td>92</td><td>57.9</td><td rowspan="2">&#8722;0.292</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;II-IV</td><td>216</td><td>152</td><td>19</td><td>19</td><td>26</td><td>29.6</td></tr><tr><td colspan="9">Lauren&#8217;s classification</td></tr><tr><td>&#160;&#160;Intestinal-type</td><td>273</td><td>108</td><td>34</td><td>38</td><td>93</td><td>60.4</td><td rowspan="2">&#8722;0.322</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;Diffuse-type</td><td>225</td><td>157</td><td>21</td><td>22</td><td>25</td><td>30.2</td></tr></tbody>
###xml 2684 3396 2677 3385 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Clinicopathological features</th><th rowspan="2">Number</th><th align="left" colspan="7">Parafibromin expression</th></tr><tr><th>&#8722;</th><th>+</th><th>++</th><th>+++</th><th>PR (%)</th><th>Rs</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="9">Age (years)</td></tr><tr><td>&#160;&#160;&lt;65</td><td>209</td><td>125</td><td>24</td><td>24</td><td>36</td><td>40.2</td><td rowspan="2">0.095</td><td rowspan="2">&lt;0.05</td></tr><tr><td>&#160;&#160;&#8805;65</td><td>299</td><td>150</td><td>31</td><td>36</td><td>82</td><td>49.8</td></tr><tr><td colspan="9">Sex</td></tr><tr><td>&#160;&#160;Male</td><td>354</td><td>188</td><td>37</td><td>38</td><td>91</td><td>46.9</td><td rowspan="2">0.054</td><td rowspan="2">&gt;0.05</td></tr><tr><td>&#160;&#160;Female</td><td>154</td><td>87</td><td>18</td><td>22</td><td>27</td><td>43.5</td></tr><tr><td colspan="9">Tumour size (cm)</td></tr><tr><td>&#160;&#160;&lt;4</td><td>263</td><td>116</td><td>26</td><td>34</td><td>85</td><td>55.9</td><td rowspan="2">&#8722;0.237</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;&#8805;4</td><td>245</td><td>159</td><td>27</td><td>26</td><td>33</td><td>35.1</td></tr><tr><td colspan="9">Depth of invasion</td></tr><tr><td>&#160;&#160;T<sub>is&#8722;1</sub></td><td>263</td><td>102</td><td>30</td><td>40</td><td>91</td><td>61.2</td><td rowspan="2">&#8722;0.344</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;T<sub>2-4</sub></td><td>245</td><td>173</td><td>25</td><td>20</td><td>27</td><td>29.4</td></tr><tr><td colspan="9">Lymphatic invasion</td></tr><tr><td>&#160;&#160;&#8722;</td><td>331</td><td>157</td><td>42</td><td>45</td><td>87</td><td>52.6</td><td rowspan="2">&#8722;0.168</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;+</td><td>177</td><td>118</td><td>13</td><td>15</td><td>31</td><td>33.3</td></tr><tr><td colspan="9">Venous invasion</td></tr><tr><td>&#160;&#160;&#8722;</td><td>443</td><td>236</td><td>49</td><td>51</td><td>107</td><td>46.7</td><td rowspan="2">&#8722;0.051</td><td rowspan="2">&gt;0.05</td></tr><tr><td>&#160;&#160;+</td><td>65</td><td>39</td><td>6</td><td>9</td><td>11</td><td>40.0</td></tr><tr><td colspan="9">Lymph node metastasis</td></tr><tr><td>&#160;&#160;&#8722;</td><td>317</td><td>138</td><td>38</td><td>44</td><td>97</td><td>56.5</td><td rowspan="2">&#8722;0.285</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;+</td><td>191</td><td>137</td><td>17</td><td>16</td><td>21</td><td>28.3</td></tr><tr><td colspan="9">UICC staging</td></tr><tr><td>&#160;&#160;0&#8211;I</td><td>292</td><td>123</td><td>36</td><td>41</td><td>92</td><td>57.9</td><td rowspan="2">&#8722;0.292</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;II-IV</td><td>216</td><td>152</td><td>19</td><td>19</td><td>26</td><td>29.6</td></tr><tr><td colspan="9">Lauren&#8217;s classification</td></tr><tr><td>&#160;&#160;Intestinal-type</td><td>273</td><td>108</td><td>34</td><td>38</td><td>93</td><td>60.4</td><td rowspan="2">&#8722;0.322</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;Diffuse-type</td><td>225</td><td>157</td><td>21</td><td>22</td><td>25</td><td>30.2</td></tr></tbody></table>
###xml 3396 3398 3385 3387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PR</italic>
###xml 3414 3415 3403 3404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 3415 3417 3404 3406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">is</italic>
###xml 3415 3417 3404 3406 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>is</italic></sub>
###xml 3437 3438 3426 3427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 3438 3439 3427 3428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 3438 3439 3427 3428 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>1</italic></sub>
###xml 3470 3471 3459 3460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 3471 3472 3460 3461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 3471 3472 3460 3461 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>2</italic></sub>
###xml 3507 3508 3496 3497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 3508 3509 3497 3498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 3508 3509 3497 3498 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>3</italic></sub>
###xml 3530 3531 3519 3520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 3531 3532 3520 3521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 3531 3532 3520 3521 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>4</italic></sub>
###xml 3555 3559 3544 3548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UICC</italic>
###xml 3396 3597 3385 3586 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><italic>PR</italic> Positive rate, <italic>T</italic><sub><italic>is</italic></sub> carcinoma in situ, <italic>T</italic><sub><italic>1</italic></sub> lamina propria and submucosa, <italic>T</italic><sub><italic>2</italic></sub> muscularis propria and subserosa, <italic>T</italic><sub><italic>3</italic></sub> exposure to serosa, <italic>T</italic><sub><italic>4</italic></sub> invasion into serosa, <italic>UICC</italic> Union Internationale Contre le Cancer</p>
###xml 3396 3597 3385 3586 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32"><italic>PR</italic> Positive rate, <italic>T</italic><sub><italic>is</italic></sub> carcinoma in situ, <italic>T</italic><sub><italic>1</italic></sub> lamina propria and submucosa, <italic>T</italic><sub><italic>2</italic></sub> muscularis propria and subserosa, <italic>T</italic><sub><italic>3</italic></sub> exposure to serosa, <italic>T</italic><sub><italic>4</italic></sub> invasion into serosa, <italic>UICC</italic> Union Internationale Contre le Cancer</p></table-wrap-foot>
###xml 2577 3597 2570 3586 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="31"> Relationship between parafibromin expression and clinicopathological features of gastric carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Clinicopathological features</th><th rowspan="2">Number</th><th align="left" colspan="7">Parafibromin expression</th></tr><tr><th>&#8722;</th><th>+</th><th>++</th><th>+++</th><th>PR (%)</th><th>Rs</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="9">Age (years)</td></tr><tr><td>&#160;&#160;&lt;65</td><td>209</td><td>125</td><td>24</td><td>24</td><td>36</td><td>40.2</td><td rowspan="2">0.095</td><td rowspan="2">&lt;0.05</td></tr><tr><td>&#160;&#160;&#8805;65</td><td>299</td><td>150</td><td>31</td><td>36</td><td>82</td><td>49.8</td></tr><tr><td colspan="9">Sex</td></tr><tr><td>&#160;&#160;Male</td><td>354</td><td>188</td><td>37</td><td>38</td><td>91</td><td>46.9</td><td rowspan="2">0.054</td><td rowspan="2">&gt;0.05</td></tr><tr><td>&#160;&#160;Female</td><td>154</td><td>87</td><td>18</td><td>22</td><td>27</td><td>43.5</td></tr><tr><td colspan="9">Tumour size (cm)</td></tr><tr><td>&#160;&#160;&lt;4</td><td>263</td><td>116</td><td>26</td><td>34</td><td>85</td><td>55.9</td><td rowspan="2">&#8722;0.237</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;&#8805;4</td><td>245</td><td>159</td><td>27</td><td>26</td><td>33</td><td>35.1</td></tr><tr><td colspan="9">Depth of invasion</td></tr><tr><td>&#160;&#160;T<sub>is&#8722;1</sub></td><td>263</td><td>102</td><td>30</td><td>40</td><td>91</td><td>61.2</td><td rowspan="2">&#8722;0.344</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;T<sub>2-4</sub></td><td>245</td><td>173</td><td>25</td><td>20</td><td>27</td><td>29.4</td></tr><tr><td colspan="9">Lymphatic invasion</td></tr><tr><td>&#160;&#160;&#8722;</td><td>331</td><td>157</td><td>42</td><td>45</td><td>87</td><td>52.6</td><td rowspan="2">&#8722;0.168</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;+</td><td>177</td><td>118</td><td>13</td><td>15</td><td>31</td><td>33.3</td></tr><tr><td colspan="9">Venous invasion</td></tr><tr><td>&#160;&#160;&#8722;</td><td>443</td><td>236</td><td>49</td><td>51</td><td>107</td><td>46.7</td><td rowspan="2">&#8722;0.051</td><td rowspan="2">&gt;0.05</td></tr><tr><td>&#160;&#160;+</td><td>65</td><td>39</td><td>6</td><td>9</td><td>11</td><td>40.0</td></tr><tr><td colspan="9">Lymph node metastasis</td></tr><tr><td>&#160;&#160;&#8722;</td><td>317</td><td>138</td><td>38</td><td>44</td><td>97</td><td>56.5</td><td rowspan="2">&#8722;0.285</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;+</td><td>191</td><td>137</td><td>17</td><td>16</td><td>21</td><td>28.3</td></tr><tr><td colspan="9">UICC staging</td></tr><tr><td>&#160;&#160;0&#8211;I</td><td>292</td><td>123</td><td>36</td><td>41</td><td>92</td><td>57.9</td><td rowspan="2">&#8722;0.292</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;II-IV</td><td>216</td><td>152</td><td>19</td><td>19</td><td>26</td><td>29.6</td></tr><tr><td colspan="9">Lauren&#8217;s classification</td></tr><tr><td>&#160;&#160;Intestinal-type</td><td>273</td><td>108</td><td>34</td><td>38</td><td>93</td><td>60.4</td><td rowspan="2">&#8722;0.322</td><td rowspan="2">&lt;0.001</td></tr><tr><td>&#160;&#160;Diffuse-type</td><td>225</td><td>157</td><td>21</td><td>22</td><td>25</td><td>30.2</td></tr></tbody></table><table-wrap-foot><p textid="32"><italic>PR</italic> Positive rate, <italic>T</italic><sub><italic>is</italic></sub> carcinoma in situ, <italic>T</italic><sub><italic>1</italic></sub> lamina propria and submucosa, <italic>T</italic><sub><italic>2</italic></sub> muscularis propria and subserosa, <italic>T</italic><sub><italic>3</italic></sub> exposure to serosa, <italic>T</italic><sub><italic>4</italic></sub> invasion into serosa, <italic>UICC</italic> Union Internationale Contre le Cancer</p></table-wrap-foot></table-wrap>
###xml 680 688 <span type="species:ncbi:9606">patients</span>
###xml 740 748 <span type="species:ncbi:9606">patients</span>
###xml 1193 1201 <span type="species:ncbi:9606">patients</span>
###xml 1596 1601 <span type="species:ncbi:9606">human</span>
As shown in Fig. 1, parafibromin was positively immunostained in the nucleus of MKN28, AGS, MKN45, KATO-III and HGC-27, and its expression level was consistent with the data of Western blot. Parafibromin was strongly expressed in the nucleus of gastric epithelial cells, adenomas and early carcinomas but not in given advanced carcinomas. Occasionally, it also appeared in stromal fibroblasts and lymphocytes but much weaker than epithelial cells or adenomas (Fig. 2).Generally, the stromal lymphocytes and fibroblasts were negative in cases where the tumour was negative. Overall, parafibromin expression was detected respectively in all gastritis (100.0%), 36 out of 45 adenoma patients (80.0%) and 233 out of total 508 gastric carcinoma patients (45.9%). Statistically, gradually reduced expression of parafibromin was seen from gastritis to gastric carcinoma through gastric adenoma (p < 0.05, Table 1). As summarised in Table 2, parafibromin expression was inversely correlated with tumour size, depth of invasion, lymphatic invasion, lymph node metastasis and UICC staging (p < 0.05) but not with sex or venous invasion (p > 0.05). Parafibromin was strongly expressed in older carcinoma patients compared with younger ones (p < 0.05). Intestinal-type carcinomas exhibited more frequent expression of parafibromin than diffuse-type ones (p < 0.05). Fig. 1Parafibromin expression in gastric carcinoma cell lines. a Parafibromin was positively immunostained in the nucleus of MKN28 (a), AGS (b), MKN45 (c), KATO-III (d) and HGC-27(e). b Cell lysate (50 microg) was loaded and probed with anti-human parafibromin antibody (60 kd) with beta-actin (42 kd) as an internal control. Lane #1: MKN28; #2 AGS; #3 MKN45; #4 KATO-III; #5 HGC-27Fig. 2Immunohistochemical staining of parafibromin in gastritis, adenoma and carcinoma. Note parafibromin positivity was strongly observed in the nucleus of gastric superficial epithelium (a), and adenoma (c) and early gastric carcinoma (b), occasionally weaker in the stromal fibroblasts and lymphocytes(a, c), but not in given advanced gastric carcinomas (d), indicating that the internal positive control (stromal cells) was negative adjacent to the negative staining carcinoma cells but positive adjacent to the positive epithelial cellsTable 1Parafibromin expression in gastric tissue samplesGroupsNumberParafibromin expression-++++++PR (%)Gastritis4901741100.0aGastric adenoma459582380.0bGastric carcinoma508275556011845.9PR Positive rateaCompared with gastric adenoma or carcinoma, p < 0.001bCompared with gastric carcinoma, p < 0.001Table 2 Relationship between parafibromin expression and clinicopathological features of gastric carcinomasClinicopathological featuresNumberParafibromin expression-++++++PR (%)Rsp valueAge (years)  <6520912524243640.20.095<0.05  >/=6529915031368249.8Sex  Male35418837389146.90.054>0.05  Female1548718222743.5Tumour size (cm)  <426311626348555.9-0.237<0.001  >/=424515927263335.1Depth of invasion  Tis-126310230409161.2-0.344<0.001  T2-424517325202729.4Lymphatic invasion  -33115742458752.6-0.168<0.001  +17711813153133.3Venous invasion  -443236495110746.7-0.051>0.05  +6539691140.0Lymph node metastasis  -31713838449756.5-0.285<0.001  +19113717162128.3UICC staging  0-I29212336419257.9-0.292<0.001  II-IV21615219192629.6Lauren's classification  Intestinal-type27310834389360.4-0.322<0.001  Diffuse-type22515721222530.2PR Positive rate, Tis carcinoma in situ, T1 lamina propria and submucosa, T2 muscularis propria and subserosa, T3 exposure to serosa, T4 invasion into serosa, UICC Union Internationale Contre le Cancer
###end p 24
###begin p 25
###xml 57 58 57 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 174 175 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e</italic>
###xml 178 179 178 179 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 320 327 313 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lane #1</italic>
###xml 336 338 329 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">#2</italic>
###xml 344 346 337 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">#3</italic>
###xml 354 356 347 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">#4</italic>
###xml 367 369 360 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">#5</italic>
###xml 236 241 <span type="species:ncbi:9606">human</span>
Parafibromin expression in gastric carcinoma cell lines. a Parafibromin was positively immunostained in the nucleus of MKN28 (a), AGS (b), MKN45 (c), KATO-III (d) and HGC-27(e). b Cell lysate (50 microg) was loaded and probed with anti-human parafibromin antibody (60 kd) with beta-actin (42 kd) as an internal control. Lane #1: MKN28; #2 AGS; #3 MKN45; #4 KATO-III; #5 HGC-27
###end p 25
###begin p 26
###xml 183 184 183 184 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 200 201 200 201 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 232 233 232 233 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 299 300 299 300 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 302 303 302 303 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 352 353 352 353 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
Immunohistochemical staining of parafibromin in gastritis, adenoma and carcinoma. Note parafibromin positivity was strongly observed in the nucleus of gastric superficial epithelium (a), and adenoma (c) and early gastric carcinoma (b), occasionally weaker in the stromal fibroblasts and lymphocytes(a, c), but not in given advanced gastric carcinomas (d), indicating that the internal positive control (stromal cells) was negative adjacent to the negative staining carcinoma cells but positive adjacent to the positive epithelial cells
###end p 26
###begin p 27
Parafibromin expression in gastric tissue samples
###end p 27
###begin p 28
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PR</italic>
PR Positive rate
###end p 28
###begin p 29
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
aCompared with gastric adenoma or carcinoma, p < 0.001
###end p 29
###begin p 30
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
bCompared with gastric carcinoma, p < 0.001
###end p 30
###begin p 31
 Relationship between parafibromin expression and clinicopathological features of gastric carcinomas
###end p 31
###begin p 32
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PR</italic>
###xml 18 19 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 19 21 19 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">is</italic>
###xml 19 21 19 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>is</italic></sub>
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 42 43 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>1</italic></sub>
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 75 76 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 75 76 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>2</italic></sub>
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 112 113 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>3</italic></sub>
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 135 136 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>4</italic></sub>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UICC</italic>
PR Positive rate, Tis carcinoma in situ, T1 lamina propria and submucosa, T2 muscularis propria and subserosa, T3 exposure to serosa, T4 invasion into serosa, UICC Union Internationale Contre le Cancer
###end p 32
###begin title 33
Univariate and multivariate survival analysis
###end title 33
###begin p 34
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 278 284 278 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kaplan</italic>
###xml 285 290 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Meier</italic>
###xml 451 452 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 771 772 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 905 906 905 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 921 922 921 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 925 931 925 931 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 1020 1026 1020 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kaplan</italic>
###xml 1027 1032 1027 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Meier</italic>
###xml 1158 1159 1158 1159 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1169 1170 1169 1170 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1172 1175 1172 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGC</italic>
###xml 1191 1192 1191 1192 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1194 1197 1194 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGC</italic>
###xml 931 1217 931 1217 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Correlation between parafibromin status and prognosis of the gastric carcinoma patients. <italic>Kaplan</italic>&#8211;<italic>Meier</italic> curves for cumulative survival rate of patients with gastric carcinomas according to the parafibromin expression in overall (<bold>a</bold>), early (<bold>b</bold>, <italic>EGC</italic>) and advanced (<bold>c</bold>, <italic>AGC</italic>) gastric carcinomas</p>
###xml 931 1217 931 1217 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Correlation between parafibromin status and prognosis of the gastric carcinoma patients. <italic>Kaplan</italic>&#8211;<italic>Meier</italic> curves for cumulative survival rate of patients with gastric carcinomas according to the parafibromin expression in overall (<bold>a</bold>), early (<bold>b</bold>, <italic>EGC</italic>) and advanced (<bold>c</bold>, <italic>AGC</italic>) gastric carcinomas</p></caption>
###xml 1217 1217 1217 1217 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="428_2007_551_Fig3_HTML" id="MO3"/>
###xml 925 1217 925 1217 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="35">Correlation between parafibromin status and prognosis of the gastric carcinoma patients. <italic>Kaplan</italic>&#8211;<italic>Meier</italic> curves for cumulative survival rate of patients with gastric carcinomas according to the parafibromin expression in overall (<bold>a</bold>), early (<bold>b</bold>, <italic>EGC</italic>) and advanced (<bold>c</bold>, <italic>AGC</italic>) gastric carcinomas</p></caption><graphic position="anchor" xlink:href="428_2007_551_Fig3_HTML" id="MO3"/></fig>
###xml 1217 1224 1217 1224 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 1224 1315 1224 1315 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Multivariate analysis of clinicopathological variables for survival with gastric carcinomas</p>
###xml 1224 1315 1224 1315 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Multivariate analysis of clinicopathological variables for survival with gastric carcinomas</p></caption>
###xml 1315 1321 1315 1321 <th xmlns:xlink="http://www.w3.org/1999/xlink">Number</th>
###xml 1321 1351 1321 1351 <th xmlns:xlink="http://www.w3.org/1999/xlink">Clinicopathological parametres</th>
###xml 1351 1372 1351 1372 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Relative risk (95%CI)</th>
###xml 1372 1373 1372 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1372 1379 1372 1379 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic> value</th>
###xml 1315 1379 1315 1379 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Number</th><th>Clinicopathological parametres</th><th align="left">Relative risk (95%CI)</th><th align="left"><italic>p</italic> value</th></tr>
###xml 1315 1379 1315 1379 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Number</th><th>Clinicopathological parametres</th><th align="left">Relative risk (95%CI)</th><th align="left"><italic>p</italic> value</th></tr></thead>
###xml 1379 1380 1379 1380 <td xmlns:xlink="http://www.w3.org/1999/xlink">A</td>
###xml 1380 1397 1380 1395 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (&#8805;65&#160;years)</td>
###xml 1397 1416 1395 1414 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.929 (1.357&#8211;2.743)</td>
###xml 1416 1422 1414 1420 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001</td>
###xml 1379 1422 1379 1420 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>A</td><td>Age (&#8805;65&#160;years)</td><td>1.929 (1.357&#8211;2.743)</td><td>&lt;0.001</td></tr>
###xml 1422 1423 1420 1421 <td xmlns:xlink="http://www.w3.org/1999/xlink">B</td>
###xml 1423 1435 1421 1433 <td xmlns:xlink="http://www.w3.org/1999/xlink">Sex (female)</td>
###xml 1435 1454 1433 1452 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.463 (0.983&#8211;2.179)</td>
###xml 1454 1459 1452 1457 <td xmlns:xlink="http://www.w3.org/1999/xlink">&gt;0.05</td>
###xml 1422 1459 1420 1457 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>B</td><td>Sex (female)</td><td>1.463 (0.983&#8211;2.179)</td><td>&gt;0.05</td></tr>
###xml 1459 1460 1457 1458 <td xmlns:xlink="http://www.w3.org/1999/xlink">C</td>
###xml 1460 1481 1458 1477 <td xmlns:xlink="http://www.w3.org/1999/xlink">Tumour size (&#8805;4&#160;cm)</td>
###xml 1481 1500 1477 1496 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.606 (1.013&#8211;2.547)</td>
###xml 1500 1505 1496 1501 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.05</td>
###xml 1459 1505 1457 1501 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>C</td><td>Tumour size (&#8805;4&#160;cm)</td><td>1.606 (1.013&#8211;2.547)</td><td>&lt;0.05</td></tr>
###xml 1505 1506 1501 1502 <td xmlns:xlink="http://www.w3.org/1999/xlink">D</td>
###xml 1526 1529 1522 1525 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#8211;4</sub>
###xml 1506 1530 1502 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink">Depth of invasion (T<sub>2&#8211;4</sub>)</td>
###xml 1530 1550 1526 1546 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.530 (3.110&#8211;13.710)</td>
###xml 1550 1556 1546 1552 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001</td>
###xml 1505 1556 1501 1552 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>D</td><td>Depth of invasion (T<sub>2&#8211;4</sub>)</td><td>6.530 (3.110&#8211;13.710)</td><td>&lt;0.001</td></tr>
###xml 1556 1557 1552 1553 <td xmlns:xlink="http://www.w3.org/1999/xlink">E</td>
###xml 1557 1579 1553 1575 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lymphatic invasion (+)</td>
###xml 1579 1598 1575 1594 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.626 (1.516&#8211;3.374)</td>
###xml 1598 1604 1594 1600 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.001</td>
###xml 1556 1604 1552 1600 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>E</td><td>Lymphatic invasion (+)</td><td>2.626 (1.516&#8211;3.374)</td><td>&lt;0.001</td></tr>
###xml 1604 1605 1600 1601 <td xmlns:xlink="http://www.w3.org/1999/xlink">F</td>
###xml 1605 1624 1601 1620 <td xmlns:xlink="http://www.w3.org/1999/xlink">Venous invasion (+)</td>
###xml 1624 1643 1620 1639 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.959 (0.633&#8211;1.452)</td>
###xml 1643 1648 1639 1644 <td xmlns:xlink="http://www.w3.org/1999/xlink">&gt;0.05</td>
###xml 1604 1648 1600 1644 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>F</td><td>Venous invasion (+)</td><td>0.959 (0.633&#8211;1.452)</td><td>&gt;0.05</td></tr>
###xml 1648 1649 1644 1645 <td xmlns:xlink="http://www.w3.org/1999/xlink">G</td>
###xml 1649 1674 1645 1670 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lymph node metastasis (+)</td>
###xml 1674 1693 1670 1689 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.773 (1.525&#8211;5.043)</td>
###xml 1693 1698 1689 1694 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.01</td>
###xml 1648 1698 1644 1694 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>G</td><td>Lymph node metastasis (+)</td><td>2.773 (1.525&#8211;5.043)</td><td>&lt;0.01</td></tr>
###xml 1698 1699 1694 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink">H</td>
###xml 1699 1719 1695 1715 <td xmlns:xlink="http://www.w3.org/1999/xlink">UICC staging (II-IV)</td>
###xml 1719 1738 1715 1734 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.294 (0.139&#8211;0.622)</td>
###xml 1738 1743 1734 1739 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.01</td>
###xml 1698 1743 1694 1739 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>H</td><td>UICC staging (II-IV)</td><td>0.294 (0.139&#8211;0.622)</td><td>&lt;0.01</td></tr>
###xml 1743 1744 1739 1740 <td xmlns:xlink="http://www.w3.org/1999/xlink">I</td>
###xml 1744 1782 1740 1778 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lauren&#8217;s classification (diffuse-type)</td>
###xml 1782 1801 1778 1797 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.796 (1.212&#8211;2.661)</td>
###xml 1801 1806 1797 1802 <td xmlns:xlink="http://www.w3.org/1999/xlink">&lt;0.01</td>
###xml 1743 1806 1739 1802 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>I</td><td>Lauren&#8217;s classification (diffuse-type)</td><td>1.796 (1.212&#8211;2.661)</td><td>&lt;0.01</td></tr>
###xml 1806 1807 1802 1803 <td xmlns:xlink="http://www.w3.org/1999/xlink">J</td>
###xml 1807 1838 1803 1834 <td xmlns:xlink="http://www.w3.org/1999/xlink">Parafibromin expression (+~+++)</td>
###xml 1838 1857 1834 1853 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.792 (0.529&#8211;1.187)</td>
###xml 1857 1862 1853 1858 <td xmlns:xlink="http://www.w3.org/1999/xlink">&gt;0.05</td>
###xml 1806 1862 1802 1858 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>J</td><td>Parafibromin expression (+~+++)</td><td>0.792 (0.529&#8211;1.187)</td><td>&gt;0.05</td></tr>
###xml 1379 1862 1379 1858 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>A</td><td>Age (&#8805;65&#160;years)</td><td>1.929 (1.357&#8211;2.743)</td><td>&lt;0.001</td></tr><tr><td>B</td><td>Sex (female)</td><td>1.463 (0.983&#8211;2.179)</td><td>&gt;0.05</td></tr><tr><td>C</td><td>Tumour size (&#8805;4&#160;cm)</td><td>1.606 (1.013&#8211;2.547)</td><td>&lt;0.05</td></tr><tr><td>D</td><td>Depth of invasion (T<sub>2&#8211;4</sub>)</td><td>6.530 (3.110&#8211;13.710)</td><td>&lt;0.001</td></tr><tr><td>E</td><td>Lymphatic invasion (+)</td><td>2.626 (1.516&#8211;3.374)</td><td>&lt;0.001</td></tr><tr><td>F</td><td>Venous invasion (+)</td><td>0.959 (0.633&#8211;1.452)</td><td>&gt;0.05</td></tr><tr><td>G</td><td>Lymph node metastasis (+)</td><td>2.773 (1.525&#8211;5.043)</td><td>&lt;0.01</td></tr><tr><td>H</td><td>UICC staging (II-IV)</td><td>0.294 (0.139&#8211;0.622)</td><td>&lt;0.01</td></tr><tr><td>I</td><td>Lauren&#8217;s classification (diffuse-type)</td><td>1.796 (1.212&#8211;2.661)</td><td>&lt;0.01</td></tr><tr><td>J</td><td>Parafibromin expression (+~+++)</td><td>0.792 (0.529&#8211;1.187)</td><td>&gt;0.05</td></tr></tbody>
###xml 1315 1862 1315 1858 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Number</th><th>Clinicopathological parametres</th><th align="left">Relative risk (95%CI)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td>A</td><td>Age (&#8805;65&#160;years)</td><td>1.929 (1.357&#8211;2.743)</td><td>&lt;0.001</td></tr><tr><td>B</td><td>Sex (female)</td><td>1.463 (0.983&#8211;2.179)</td><td>&gt;0.05</td></tr><tr><td>C</td><td>Tumour size (&#8805;4&#160;cm)</td><td>1.606 (1.013&#8211;2.547)</td><td>&lt;0.05</td></tr><tr><td>D</td><td>Depth of invasion (T<sub>2&#8211;4</sub>)</td><td>6.530 (3.110&#8211;13.710)</td><td>&lt;0.001</td></tr><tr><td>E</td><td>Lymphatic invasion (+)</td><td>2.626 (1.516&#8211;3.374)</td><td>&lt;0.001</td></tr><tr><td>F</td><td>Venous invasion (+)</td><td>0.959 (0.633&#8211;1.452)</td><td>&gt;0.05</td></tr><tr><td>G</td><td>Lymph node metastasis (+)</td><td>2.773 (1.525&#8211;5.043)</td><td>&lt;0.01</td></tr><tr><td>H</td><td>UICC staging (II-IV)</td><td>0.294 (0.139&#8211;0.622)</td><td>&lt;0.01</td></tr><tr><td>I</td><td>Lauren&#8217;s classification (diffuse-type)</td><td>1.796 (1.212&#8211;2.661)</td><td>&lt;0.01</td></tr><tr><td>J</td><td>Parafibromin expression (+~+++)</td><td>0.792 (0.529&#8211;1.187)</td><td>&gt;0.05</td></tr></tbody></table>
###xml 1862 1864 1858 1860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CI</italic>
###xml 1886 1890 1882 1886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UICC</italic>
###xml 1862 1929 1858 1925 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><italic>CI</italic> Confidence interval, <italic>UICC</italic>= Union Internationale Contre le Cancer</p>
###xml 1862 1929 1858 1925 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37"><italic>CI</italic> Confidence interval, <italic>UICC</italic>= Union Internationale Contre le Cancer</p></table-wrap-foot>
###xml 1217 1929 1217 1925 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="36">Multivariate analysis of clinicopathological variables for survival with gastric carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Number</th><th>Clinicopathological parametres</th><th align="left">Relative risk (95%CI)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td>A</td><td>Age (&#8805;65&#160;years)</td><td>1.929 (1.357&#8211;2.743)</td><td>&lt;0.001</td></tr><tr><td>B</td><td>Sex (female)</td><td>1.463 (0.983&#8211;2.179)</td><td>&gt;0.05</td></tr><tr><td>C</td><td>Tumour size (&#8805;4&#160;cm)</td><td>1.606 (1.013&#8211;2.547)</td><td>&lt;0.05</td></tr><tr><td>D</td><td>Depth of invasion (T<sub>2&#8211;4</sub>)</td><td>6.530 (3.110&#8211;13.710)</td><td>&lt;0.001</td></tr><tr><td>E</td><td>Lymphatic invasion (+)</td><td>2.626 (1.516&#8211;3.374)</td><td>&lt;0.001</td></tr><tr><td>F</td><td>Venous invasion (+)</td><td>0.959 (0.633&#8211;1.452)</td><td>&gt;0.05</td></tr><tr><td>G</td><td>Lymph node metastasis (+)</td><td>2.773 (1.525&#8211;5.043)</td><td>&lt;0.01</td></tr><tr><td>H</td><td>UICC staging (II-IV)</td><td>0.294 (0.139&#8211;0.622)</td><td>&lt;0.01</td></tr><tr><td>I</td><td>Lauren&#8217;s classification (diffuse-type)</td><td>1.796 (1.212&#8211;2.661)</td><td>&lt;0.01</td></tr><tr><td>J</td><td>Parafibromin expression (+~+++)</td><td>0.792 (0.529&#8211;1.187)</td><td>&gt;0.05</td></tr></tbody></table><table-wrap-foot><p textid="37"><italic>CI</italic> Confidence interval, <italic>UICC</italic>= Union Internationale Contre le Cancer</p></table-wrap-foot></table-wrap>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 336 344 <span type="species:ncbi:9606">patients</span>
###xml 1010 1018 <span type="species:ncbi:9606">patients</span>
###xml 1072 1080 <span type="species:ncbi:9606">patients</span>
Follow-up information was available on 508 gastric carcinoma patients for periods ranging from 0.2 months to 12.2 years (median = 67.2 months). Figure 3 showed survival curves stratified according to parafibromin expression for gastric carcinomas. Univariate analysis using the Kaplan-Meier method indicated cumulative survival rate of patients with weak, moderate or strong parafibromin expression to be obviously higher than without its expression (p < 0.05; Fig. 3a). The significant difference disappeared if stratified according to the depth of invasion (Fig. 3b, c). Multivariate analysis using Cox' s proportional hazard model indicated that age, tumour size, depth of invasion, lymphatic invasion, lymph node metastasis, UICC staging and Lauren's classification (p < 0.05) but not sex, venous invasion or parafibromin expression were independent prognostic factors for overall gastric carcinomas (p > 0.05; Table 3). Fig. 3Correlation between parafibromin status and prognosis of the gastric carcinoma patients. Kaplan-Meier curves for cumulative survival rate of patients with gastric carcinomas according to the parafibromin expression in overall (a), early (b, EGC) and advanced (c, AGC) gastric carcinomasTable 3Multivariate analysis of clinicopathological variables for survival with gastric carcinomasNumberClinicopathological parametresRelative risk (95%CI)p valueAAge (>/=65 years)1.929 (1.357-2.743)<0.001BSex (female)1.463 (0.983-2.179)>0.05CTumour size (>/=4 cm)1.606 (1.013-2.547)<0.05DDepth of invasion (T2-4)6.530 (3.110-13.710)<0.001ELymphatic invasion (+)2.626 (1.516-3.374)<0.001FVenous invasion (+)0.959 (0.633-1.452)>0.05GLymph node metastasis (+)2.773 (1.525-5.043)<0.01HUICC staging (II-IV)0.294 (0.139-0.622)<0.01ILauren's classification (diffuse-type)1.796 (1.212-2.661)<0.01JParafibromin expression (+~+++)0.792 (0.529-1.187)>0.05CI Confidence interval, UICC= Union Internationale Contre le Cancer
###end p 34
###begin p 35
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kaplan</italic>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Meier</italic>
###xml 227 228 227 228 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 238 239 238 239 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 241 244 241 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGC</italic>
###xml 260 261 260 261 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 263 266 263 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGC</italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Correlation between parafibromin status and prognosis of the gastric carcinoma patients. Kaplan-Meier curves for cumulative survival rate of patients with gastric carcinomas according to the parafibromin expression in overall (a), early (b, EGC) and advanced (c, AGC) gastric carcinomas
###end p 35
###begin p 36
Multivariate analysis of clinicopathological variables for survival with gastric carcinomas
###end p 36
###begin p 37
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CI</italic>
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UICC</italic>
CI Confidence interval, UICC= Union Internationale Contre le Cancer
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 503 504 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 782 783 782 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 785 786 785 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 788 789 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 791 792 791 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 798 800 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1112 1114 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1277 1278 1277 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 1280 1281 1280 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1448 1450 1448 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1452 1454 1452 1454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
HRPT2 has been isolated from complementary DNA libraries of parathyroid, kidney and bone tissue and encodes tumour suppressor protein parafibromin [4]. In the present study, the nuclear expression pattern was observed in the gastric epithelial cells, adenomas, adenocarcinomas and carcinoma cell lines consistent with previous reports in the gastric superficial mucosa, hepatocytes, kidney cortex tubules, adrenal gland, spleen lymphocytes, parathyroid tissue, adenoma and carcinomas, breast carcinoma [5, 8, 17, 19]. Although the result was in contrast with the paper of Porzionato et al. [17] possibly due to different incubation times of primary antibody, the great majority of immunohistochemical and cell transfection studies supported our observation of the nuclear staining [2, 5, 6, 8, 14, 19]. This study again demonstrates that parafibromin is nuclear and not cytoplasmic or nucleocytoplasmic in location as initially thought. The weaker expression of parafibromin in stromal cells than epithelial cells and adenoma might be due to the specificity of its cellular distribution as described previously [17]. It was found that the translocation of parafibromin to the nuclear compartment involved a function monopartite nuclear localisation signal at residues 136-139 [2, 6]. Parafibromin is a component of Paf1 complex in the nucleus, where it plays a role in cell cycle regulation, histone methylation, lipid and nucleic acid metabolism [10, 17]. The distribution pattern of parafibromin protein in gastric epithelial cells or tumour cells demonstrated its biological function in the nucleus.
###end p 39
###begin p 40
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
Statistically, parafibromin expression was gradually reduced from gastritis to carcinoma through adenoma in line with parathyroid carcinogenesis, suggesting that downregulated parafibromin expression might contribute to the malignant transformation of gastric epithelial cells as an early event. The positive rate of parafibromin expression was reduced to 80% in gastric adenoma and reached about 46% of gastric adenocarcinoma, supporting the involvement of parafibromin in the gastric adenoma-adenocarcinoma sequence. Actually, the adenoma can progress into and be incorporated with gastric well-differentiated carcinoma when it grows bigger and de novo carcinogenesis is well understood, especially in diffuse-type gastric carcinomas [34]. Higher parafibromin expression in adenoma and intestinal-type carcinoma indicated that decreased parafibromin expression might play an important role in de novo diffuse-type carcinogenesis but less in intestinal carcinogenic pathway.
###end p 40
###begin p 41
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1059 1061 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1227 1229 1227 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 789 799 <span type="species:ncbi:7227">Drosophila</span>
###xml 814 819 <span type="species:ncbi:9606">human</span>
A body of evidences indicated that downregulation of tumour suppressor protein expression was due to genetic or epigenetic changes, like allelic loss, mutation, loss of heterozygosity (LOH), hypermethylation and microsatellite instability in malignancies [29, 30]. In the sporadic parathyroid carcinomas and hyperparathyroidism-jaw tumours, LOH or mutation of HRPT2 might cause the loss and inactivation of parafibromin protein [20, 25, 26]. Furthermore, the reduced expression of parafibromin was found to closely link to the tumour size, depth of invasion, lymphatic or venous invasion and UICC staging in line with the observation in breast carcinomas [19], indicating the inhibitory effects of parafibromin on tumour growth, invasion, metastasis and progression of gastric carcinomas. Drosophila Hyrax and its human orthologue, parafibromin, are required for nuclear transduction of the Wnt/Wg signal and bind directly to the C-terminal region of beta-catenin-Armadillo, thereby controlling transcriptional initiation and elongation by RNA polymerase II [15]. Parafibromin overexpression can inhibit colony formation, anchorage-dependent cell growth and cellular proliferation and induce cell cycle arrest in the G1 phase [28]. These findings demonstrated that loss of parafibromin expression had impact on the pathogenesis and progression of malignancies by promoting cellular proliferation. Additionally, parafibromin was expressed with a higher incidence in intestinal-type gastric cancer, which is presumed to arise from preceding dysplastic lesions, than diffuse-type one, which evolves without any precedent dysplastic changes. It is also demonstrated that distinct parafibromin expression underlies the molecular mechanisms for the differentiation of intestinal- and diffuse-type carcinomas.
###end p 41
###begin p 42
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 913 921 <span type="species:ncbi:9606">patients</span>
Until now, there is yet no paper describing the prognostic significance of parafibromin expression in malignancies. Here, for the first time, we analysed the relation of parafibromin expression with the survival rate of 508 patients with gastric carcinoma. The results revealed a close link between its loss and worse survival. If stratified according to the depth of invasion, the significant link disappeared, indicating that the relationship between parafibromin expression and prognosis depends on the depth of invasion. The multivariate analysis demonstrated that age, depth of invasion, lymphatic invasion, lymph node metastasis, UICC staging and Lauren's classification but not parafibromin expression, venous invasion or sex were independent prognostic factors for carcinomas. These findings suggested that parafibromin expression is a promising indicator for the favorable prognosis of gastric carcinoma patients, albeit not independent.
###end p 42
###begin p 43
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
In the present study, a large number of gastric carcinoma cases were screened by TMA, which takes the advantages of high throughput, identical immunohistochemical conditions, and economy of samples, antibodies and time [33]. Although we used 2-mm-in-diametre needles, which are large enough to evaluate the morphological appearance and carefully selected representative regions with the reference of HE slides, it was difficult to avoid selection bias. Gill et al. [5] found that stronger parafibromin staining and more positive cells sometimes appeared at the edges of the parathyroid tumour than in the centre. This could be due to fixation methods, other processing issues or a biological phenomenon, for example tissue hypoxia in the centre of large tumours. Additionally, the collection of our samples (e.g. gastritis, adenoma and adenocarcinoma) respectively from the endoscopic biopsy, polypectomy, or surgical resection put forward their another possibility of selection bias because of different fixation and processing methods. Selvarajan et al. [19] found that parafibromin underexpression was correlated particularly with large tumour size which is in line with our finding. It was possible that weaker staining could be attributable to poor fixation properties in the centre of large tumours. Because tumour size is a key prognostic indicator, this artifact could explain the prognostic significance of parafibromin in gastric carcinomas. Therefore, it is a limitation of the present study not to separate the edge and centre of gastric carcinomas when establishing TMA. In the current study, the negatively staining carcinomas are associated with a negative internal control (stromal cells and lymphocytes) whereas the positive staining epithelium is adjacent to positive staining internal controls. Therefore, the negative staining of the carcinoma might be artificial, which should be considered as another limitation of the study. Our study might be mentioned as a preliminary experiment and the staining with original-size sections is an extensive work in the future using the gastric carcinoma samples, fixed and processed by the same approach.
###end p 43
###begin p 44
In summary, downregulated parafibromin expression might play an important role in malignant transformation of gastric epithelial cells. Its reduced expression was closely related to growth, invasion, metastasis and worse prognosis of gastric carcinomas. Its expression could be employed to differentiate the intestinal- and diffuse-type carcinomas and underlay the molecular mechanism about the differentiation of both carcinomas. It was considered as a promising marker to indicate the pathobiological behaviours and prognosis of gastric carcinomas.
###end p 44
###begin title 45
Acknowledgements
###end title 45
###begin p 46
We particularly thanked Kanako Yasuyoshi, Tokimasa Kumada and Hideki Hatta for their technical help and Yukari Inoue for her secretarial assistance. This work was partially supported by the Japanese Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Scientific Research 14770072, Japanese Smoking Foundation and Shenyang Outstanding Scholar Foundation.
###end p 46
###begin p 47
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Conflict of interest statement</bold>
Conflict of interest statement No conflict of interest
###end p 47
###begin title 48
References
###end title 48
###begin article-title 49
Dental findings in a family with hyperparathyroidism-jaw tumour syndrome and a novel HRPT2 gene mutation
###end article-title 49
###begin article-title 50
Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal
###end article-title 50
###begin article-title 51
Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism
###end article-title 51
###begin article-title 52
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumour syndrome
###end article-title 52
###begin article-title 53
Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumour (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias
###end article-title 53
###begin article-title 54
Identification of a functional bipartite nuclear localization signal in the tumour suppressor parafibromin
###end article-title 54
###begin article-title 55
HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours
###end article-title 55
###begin article-title 56
Loss of parafibromin expression in a subset of parathyroid adenomas
###end article-title 56
###begin article-title 57
Gastric cancer epidemiology and risk factors
###end article-title 57
###begin article-title 58
The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation
###end article-title 58
###begin article-title 59
Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital
###end article-title 59
###begin article-title 60
Gastric carcinoma in its early stages
###end article-title 60
###begin article-title 61
The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification
###end article-title 61
###begin article-title 62
Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function
###end article-title 62
###begin article-title 63
Parafibromin/hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo
###end article-title 63
###begin article-title 64
HRPT2 gene alterations in ossifying fibroma of the jaws
###end article-title 64
###begin article-title 65
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
###xml 60 65 <span type="species:ncbi:9606">human</span>
Immunohistochemical assessment of parafibromin in mouse and human tissues
###end article-title 65
###begin article-title 66
###xml 56 61 <span type="species:ncbi:9606">human</span>
The parafibromin tumour suppressor protein is part of a human Paf1 complex
###end article-title 66
###begin article-title 67
Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma
###end article-title 67
###begin article-title 68
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma
###end article-title 68
###begin article-title 69
HRPT2, a tumour suppressor gene for hyperparathyroidism-jaw tumour syndrome
###end article-title 69
###begin article-title 70
Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter
###end article-title 70
###begin article-title 71
Parafibromin, product of the hyperparathyroidism-jaw tumour syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression
###end article-title 71
###begin article-title 72
Geographic pathology on the precursors of stomach cancer
###end article-title 72
###begin article-title 73
###xml 70 75 <span type="species:ncbi:9606">human</span>
The HRPT2 tumour suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II
###end article-title 73
###begin article-title 74
Parafibromin inhibits cancer cell growth and causes G1 phase arrest
###end article-title 74
###begin article-title 75
Role of PTEN and MMP-7 expression in growth, invasion, metastasis and angiogenesis of gastric carcinoma
###end article-title 75
###begin article-title 76
Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray
###end article-title 76
###begin article-title 77
Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis
###end article-title 77
###begin article-title 78
MUC6 down-regulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue microarrays
###end article-title 78

